坎伯兰药业 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the quarterly period ended March 31, 2026 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the transition period fromto. Commission file number: 001-33637 Cumberland Pharmaceuticals Inc. (615) 255-0068(Registrant’s Telephone Number, Including Area Code) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has beensubject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files.)Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of"large accelerated filer,""accelerated filer,""smaller reporting company"and"emerginggrowthcompany"inRule12b-2oftheExchangeAct. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant toSection 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ CUMBERLAND PHARMACEUTICALS INC.INDEX PART I – FINANCIAL INFORMATION1Item1. Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets1Condensed Consolidated Statements of Operations2Condensed Consolidated Statements of Cash Flows3Condensed Consolidated Statements of Equity4Notes to the Condensed Consolidated Financial Statements5Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item3. Quantitative and Qualitative Disclosures About Market Risk30Item4. Controls and Procedures31PART II – OTHER INFORMATION32Item1. Legal Proceedings32Item1A. Risk Factors32Item2. Unregistered Sales of Equity Securities and Use of Proceeds32Item 5. Other Information32Item6. Exhibits#SIGNATURES34 PART I – FINANCIAL INFORMATION CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Operations(Unaudited) CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows(Unaudited) CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Equity(Unaudited) CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESNotes to Condensed Consolidated Financial Statements(Unaudited) (1) ORGANIZATION AND BASIS OF PRESENTATION Cumberland Pharmaceuticals Inc. ("Cumberland," the "Company," or as used in the context of "we," "us," or "our"), is a specialtypharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. Weare dedicated to our mission of working together to provide unique products that improve the quality of patient care. Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized byrelatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote ourapproved products through our hospital, field and oncology sales forces in the United States. We continue to build a network ofestablished international partners with the needed regulatory and commercial capabilities to register and provide our medicines topatients in their countries. Cumberland’s growth strategy involves maximizing the potential of our existing brands, while continuing to build a portfolio ofdifferentiated products. Our current portfolio includes seven products approved by the U.S. Food and Drug Administration ("FDA") inthe United States. We also continue to build international partnerships to bring our medicines to patients in other countries.Additionally, we look for opportunities to expand our brands into new patient populations through clinical trials, new productpresentations and our support of select, investigator-initiated studies. Meanwhile, our clinical team is developing a pipeline of newproduct candidates to address poorly met medical needs. We also pursue opportunities to acquire additional marketed brands as well aslate-stage development product candidates in our target medical specialties. The Company’s products are manufactured by third parties, which are overseen by our quality control and manufacturingprofessionals. We work closely with our warehousing and distribution partners to m